What You Should Know:
- President Donald J. Trump announced the latest in a series of significant actions to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk.
- The initiative delivers historic price reductions on some of the world’s most popular drugs, impacting millions of Americans struggling with chronic diseases, diabetes, heart disease, and obesity.
Price Reductions for Patients and
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Tandem Diabetes Care Launches t:slim X2 Pump Integration with Abbott FreeStyle Libre 3 Plus Sensor
What You Should Know:
- Tandem Diabetes Care, Inc. today announced that its t:slim X2 insulin pump, featuring the advanced Control-IQ+ automated insulin delivery (AID) technology, is now available with the integration of Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United States.
- The launch represents the first step in a global commercial rollout, expanding choice and personalization for people worldwide living with diabetes.
Unifying
Read More
Tandem Diabetes Care’s t:slim X2 Pump Cleared for Use with Lilly’s Ultra-Rapid Lyumjev® Insulin
What You Should Know:
- Tandem Diabetes Care, an insulin delivery and diabetes technology company, has announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company’s Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).
- The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2
Read More
Arecor and Sequel to Co-Develop Next-Generation Insulin Delivery
What You Should Know:
- Arecor Therapeutics, a biopharmaceutical company specializing in drug development and delivery, has announced two major strategic achievements: a co-development agreement with Sequel Med Tech and a royalty financing agreement with Ligand Pharmaceuticals Incorporated.
- The dual strategy is intended to accelerate the clinical development of its lead product, AT278, and extend the company's cash runway without diluting shareholders.
Co-Development:
Read More
The High Cost of Non-Adherence: AI-Powered Interventions Save Medicare $10M in Diabetes Care
The U.S. healthcare system is at a critical inflection point, especially when it comes to managing chronic disease, which is why the new administration in the U.S. is beginning deep-dive discussions on how best to tackle the growing issues — both human and cost related — tied to chronic diseases, like diabetes.
With over half of adults living with at least one chronic condition — and more than 38 million Americans diagnosed with diabetes — the economic and human cost is
Read More
Glooko Acquires Monarch Medical to Unify Diabetes Management
What You Should Know:
- Glooko, a provider of remote patient monitoring and digital health solutions for diabetes, has acquired Monarch Medical Technologies, the developer of the EndoTool® Glucose Management System. Terms of the acquisition are not being disclosed.
- The strategic acquisition allows Glooko to expand its connected care capabilities into inpatient glycemic management, complementing its existing strength in outpatient diabetes management. The goal is to create a single,
Read More
Senseonics to Take Over Eversense 365 Commercialization from Ascensia
What You Should Know:
- Senseonics Holdings, a medical technology company specializing in implantable continuous glucose monitoring (CGM) systems, has announced a Memorandum of Understanding (MOU) with Ascensia Diabetes Care to transition all global commercialization and distribution of its Eversense 365 and future products to Senseonics. Since 2020, Ascensia, a member of PHC Group, has held the exclusive worldwide distribution rights for Eversense products.
This strategic move is
Read More
Reach7 Diabetes Studios and Trileas Partner to Launch CARES Program for At-Risk Communities
What You Should Know:
- Reach7 Diabetes Studios has announced that Trileas is the first official sponsor and founding member of its CARES Program. The program is a third-party sponsored initiative that provides screenings for high-risk individuals and subsidized memberships for those most in need.
- The partnership with Trileas, a company dedicated to delivering affordable connectivity and healthcare solutions, will help the CARES Program reach further, expand access, and transform
Read More
Carna Health & Siemens Healthineers Partner to Advance AI-Powered CKD Screening
What You Should Know:
- Carna Health, a digital health company focused on kidney care, has announced a strategic agreement with Siemens Healthineers. The collaboration aims to accelerate the adoption of Carna's AI-enabled chronic kidney disease (CKD) platform and bring point-of-care testing systems to emerging markets.
- This will help improve early detection and CKD management for high-risk and underserved populations by integrating Carna Health’s digital platforms with Siemens
Read More
FriskaAi Integrates with Dexcom’s CGM Data for AI-Powered Diabetes Management
What You Should Know:
- FriskaAi, an AI-powered healthcare platform, has announced an agreement with Dexcom, Inc., a global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into its platform.
- The collaboration will enable FriskaAi to use continuous glucose data to support physicians and patients with actionable, personalized care management programs.
Physician-Directed Platform for Chronic Disease
Read More
